Analyst & Firm | Company | Price | Rating & Price Target | Upside / Downside | Success Rate | Average Return | Action | Date | Article |
---|---|---|---|---|---|---|---|---|---|
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $21 | ― | 25.90% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $53 | ― | 3.90% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $680→$720 | ― | 16.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $64→$61 | ― | 0.40% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $65 | ― | 5.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $67 | ― | 4.10% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $96 | ― | 6.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $18 | ― | 3.30% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $118 | ― | 6.90% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $276 | ― | 1.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $44 | ― | 13.00% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $8 | ― | 29.80% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $205→$189 | ― | 16.80% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $20 | ― | 5.90% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $22 | ― | 5.90% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $390→$429 | ― | 7.20% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $365→$350 | ― | 17.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $228→$270 | ― | 11.60% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $240→$260 | ― | 11.30% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $220→$227 | ― | 8.60% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $29→$27 | ― | 7.20% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $386 | ― | 5.70% | Reiterated | ||||
Domino's Pizza | BUY $496 | ― | 0.10% | Reiterated | Positive Outlook for Domino's Pizza: Growth Catalysts and Market Positioning Highlighted in Analyst Report | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $130 | ― | 11.10% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $290 | ― | 13.20% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $400→$420 | ― | 19.00% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $180→$195 | ― | 19.00% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $160→$165 | ― | 19.00% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $74→$80 | ― | 19.00% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD | ― | 8.00% | Downgraded | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $100→$87 | ― | 2.20% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $133→$153 | ― | 3.40% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $12 | ― | 5.10% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $7 | ― | 6.30% | Reiterated | ||||
Valneva | BUY $18→$17 | ― | -5.00% | Reiterated | Valneva's Promising Growth and Strategic Positioning: Buy Rating Affirmed by Edward White | ||||
Liberty Global A | HOLD $12.5 | ― | -1.80% | Reiterated | Analysts Conflicted on These Communication Services Names: News Corp (NASDAQ: NWSA), Verizon (NYSE: VZ) and Liberty Global A (NASDAQ: LBTYA) | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $24 | ― | 1.40% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $325 | ― | 5.20% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $54 | ― | 7.20% | Reiterated | ||||
BridgeBio Pharma | BUY $46 | ― | -2.20% | Reiterated | Piper Sandler Reaffirms Their Buy Rating on BridgeBio Pharma (BBIO) | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $145 | ― | 2.20% | Reiterated | ||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $140→$135 | ― | 51.50% | Reiterated | |||||
xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $64 | ― | 0.20% | Reiterated | |||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $60 | ― | 14.30% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | BUY $35 | ― | 2.20% | Reiterated | ||||
Abeona Therapeutics | BUY $15 | ― | -17.60% | Reiterated | Abeona Therapeutics: Promising Pipeline and Key Approvals Drive Buy Rating | ||||
Omnicell | BUY $69 | ― | -3.20% | Reiterated | Analysts Are Bullish on Top Healthcare Stocks: Penumbra (PEN), Omnicell (OMCL) | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $31 | ― | 4.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | HOLD $56 | ― | 4.70% | Reiterated | ||||
![]() | xxxxxxxxxxxxxxxxxxxxxxxxxxx | SELL $6 | ― | 7.20% | Reiterated |